Rapid degradation of hypoxia-inducible factor-1α by KRH102053, a new activator of prolyl hydroxylase 2

British Journal of Pharmacology

Volumn 154, Issue 1, 2008, Pages 114-125

  Choi, H J ^a   Song, B J ^b   Gong, Y D ^c   Gwak, W J ^d   Soh, Y ^a  

^a Chonbuk National University   (South Korea)

^b NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^c Korea Research Institute of Chemical Technology   (South Korea)

^d SK Chemicals   (South Korea)

Author keywords

Hypoxia; Hypoxia inducible factor; Invasion; KRH102053; Prolyl hydroxylase; Vascular endothelial growth factor

Indexed keywords

2 AMINO 4 METHYLSULFANYLBUTYLIC ACID 4 METHOXY (4 METHOXYBENZYLAMINO) 2,2 DIMETHYLCHROMAN 3 YL ESTER; BENZOPYRAN DERIVATIVE; CHROMAN DERIVATIVE; ENOLASE; ENOLASE 1; ENZYME ACTIVATOR; FRUCTOSE BISPHOSPHATE ALDOLASE; FRUCTOSE BISPHOSPHATE ALDOLASE ISOENZYME; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KRH 102053; MESSENGER RNA; MONOCARBOXYLATE TRANSPORTER 4; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROLYL HYDROXYLASE 2; PROTEASOME; UBIQUITIN; VASCULOTROPIN;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL LINE; CELL STRAIN HEPG2; CONTROLLED STUDY; CULTURE MEDIUM; DRUG STRUCTURE; ENDOTHELIUM CELL; ENZYME ACTIVATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROXYLATION; MOLECULAR LIBRARY; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOSARCOMA; PHEOCHROMOCYTOMA CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; RAT; UMBILICAL VEIN;

EID: 42949106526     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.70     Document Type: Article

References (43)

1. Appelhoff RJ, Tian YM, Raval RR, Turley H, Harris AL, Pugh CW et al. (2004). Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia‐inducible factor. J Biol Chem 279: 38458–38465.
2. Bos R, Van Diest PJ, De Jong JS, Van Der Groep P, Van Der Valk P, Van Der Wall E (2005). Hypoxia‐inducible factor‐1alpha is associated with angiogenesis, and expression of bFGF, PDGF‐BB, and EGFR in invasive breast cancer. Histopathology 46: 31–36.
3. Bruick RK, McKnight SL (2001). A conserved family of prolyl‐4‐hydroxylases that modify HIF. Science 294: 1337–1340.
4. Bussolati B, Dunk C, Grohman M, Kontos CD, Mason J, Ahmed A (2001). Vascular endothelial growth factor receptor‐1 modulates vascular endothelial growth factor‐mediated angiogenesis via nitric oxide. Am J Pathol 159: 993–1008.
5. Chen Y, Zhang YX, Li MH, Zhao WM, Shi YH, Miao ZH et al. (2005). Antiangiogenic activity of 11,11′‐dideoxyverticillin, a natural product isolated from the fungus Shiraia bambusicola. Biochem Biophys Res Commun 329: 1334–1342.
6. Choi H, Chun YS, Kim SW, Kim MS, Park JW (2006). Curcumin inhibits hypoxia‐inducible factor‐1 by degrading aryl hydrocarbon receptor nuclear translocator: a mechanism of tumor growth inhibition. Mol Pharmacol 70: 1664–1671.
7. Fernandez‐Sauze S, Delfino C, Mabrouk K, Dussert C, Chinot O, Martin PM et al. (2004). Effects of adrenomedullin on endothelial cells in the multistep process of angiogenesis: involvement of CRLR/RAMP2 and CRLR/RAMP3 receptors. Int J Cancer 108: 797–804.
8. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD et al. (1996). Activation of vascular endothelial growth factor gene transcription by hypoxia‐inducible factor 1. Mol Cell Biol 16: 4604–4613.
9. Frede S, Freitag P, Otto T, Heilmaier C, Fandrey J (2005). The proinflammatory cytokine interleukin 1beta and hypoxia cooperatively induce the expression of adrenomedullin in ovarian carcinoma cells through hypoxia inducible factor 1 activation. Cancer Res 65: 4690–4697.
10. Gong YD, Seo JS, Chon YS, Hwang JY, Park JY, Yoo SE (2003). Construction of 6‐amino‐2,2‐dimethyl‐3,4,6‐trisubstituted‐2 H ‐1‐benzopyran library by solid phase synthesis. J Comb Chem 5: 577–589.
11. Groulx I, Lee S (2002). Oxygen‐dependent ubiquitination and degradation of hypoxia‐inducible factor requires nuclear‐cytoplasmic trafficking of the von Hippel–Lindau tumor suppressor protein. Mol Cell Biol 22: 5319–5336.
12. Hirota K, Semenza GL (2005). Regulation of hypoxia‐inducible factor 1 by prolyl and asparaginyl hydroxylases. Biochem Biophys Res Commun 338: 610–616.
13. Hirsila M, Koivunen P, Gunzler V, Kivirikko KI, Myllyharju J (2003). Characterization of the human prolyl 4‐hydroxylases that modify the hypoxia‐inducible factor. J Biol Chem 278: 30772–30780.
14. Hopfer U, Hopfer H, Jablonski K, Stahl RA, Wolf G (2006). The novel WD‐repeat protein Morg1 acts as a molecular scaffold for hypoxia‐inducible factor prolyl hydroxylase 3 (PHD3). J Biol Chem 281: 8645–8655.
15. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ et al. (2001). Targeting of HIF‐alpha to the von Hippel–Lindau ubiquitylation complex by O 2 ‐regulated prolyl hydroxylation. Science 292: 468–472.
16. Jokilehto T, Rantanen K, Luukkaa M, Heikkinen P, Grenman R, Minn H et al. (2006). Overexpression and nuclear translocation of hypoxia‐inducible factor prolyl hydroxylase PHD2 in head and neck squamous cell carcinoma is associated with tumor aggressiveness. Clin Cancer Res 12: 1080–1087.
17. Kamura T, Brower CS, Conaway RC, Conaway JW (2002). A molecular basis for stabilization of the von Hippel–Lindau (VHL) tumor suppressor protein by components of the VHL ubiquitin ligase. J Biol Chem 277: 30388–30393.
18. Ke Q, Costa M (2006). Hypoxia‐inducible factor‐1 (HIF‐1). Mol Pharmacol 70: 1469–1480.
19. Kong D, Park EJ, Stephen AG, Calvani M, Cardellina JH, Monks A et al. (2005). Echinomycin, a small‐molecule inhibitor of hypoxia‐inducible factor‐1 DNA‐binding activity. Cancer Res 65: 9047–9055.
20. Krishnamachary B, Berg‐Dixon S, Kelly B, Agani F, Feldser D, Ferreira G et al. (2003). Regulation of colon carcinoma cell invasion by hypoxia‐inducible factor 1. Cancer Res 63: 1138–1143.
21. Lee JW, Bae SH, Jeong JW, Kim SH, Kim KW (2004). Hypoxia‐inducible factor (HIF‐1)alpha: its protein stability and biological functions. Exp Mol Med 36: 1–12.
22. Marx J (2004). Cell biology. How cells endure low oxygen. Science 303: 1454–1456.
23. Matou S, Colliec‐Jouault S, Galy‐Fauroux I, Ratiskol J, Sinquin C, Guezennec J et al. (2005). Effect of an oversulfated exopolysaccharide on angiogenesis induced by fibroblast growth factor‐2 or vascular endothelial growth factor in vitro. Biochem Pharmacol 69: 751–759.
24. McNeill LA, Hewitson KS, Gleadle JM, Horsfall LE, Oldham NJ, Maxwell PH et al. (2002). The use of dioxygen by HIF prolyl hydroxylase (PHD1). Bioorg Med Chem Lett 12: 1547–1550.
25. Metzen E, Berchner‐Pfannschmidt U, Stengel P, Marxsen JH, Stolze I, Klinger M et al. (2003). Intracellular localisation of human HIF‐1 alpha hydroxylases: implications for oxygen sensing. J Cell Sci 116: 1319–1326.
26. Mueller MD, Vigne JL, Minchenko A, Lebovic DI, Leitman DC, Taylor RN (2000). Regulation of vascular endothelial growth factor (VEGF) gene transcription by estrogen receptors alpha and beta. Proc Natl Acad Sci USA 97: 10972–10977.
27. Mylonis I, Chachami G, Samiotaki M, Panayotou G, Paraskeva E, Kalousi A et al. (2006). Identification of MAPK phosphorylation sites and their role in the localization and activity of hypoxia‐inducible factor 1a. J Biol Chem 281: 33095–33106.
28. Nissi R, Bohling T, Autio‐Harmainen H (2004). Immunofluorescence localization of prolyl 4‐hydroxylase isoenzymes and type I and II collagens in bone tumours: type I enzyme predominates in osteosarcomas and chondrosarcomas, whereas type II enzyme predominates in their benign counterparts. Acta Histochem 106: 111–121.
29. Pouyssegur J, Dayan F, Mazure NM (2006). Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441: 437–443.
30. Semenza GL (2000). HIF‐1 and human disease: one highly involved factor. Genes Dev 14: 1983–1991.
31. Semenza GL (2003). Targeting HIF‐1 for cancer therapy. Nat Rev Cancer 3: 721–732.
32. Semenza GL, Roth PH, Fang HM, Wang GL (1994). Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia‐inducible factor 1. J Biol Chem 269: 23757–23763.
33. Shweiki D, Itin A, Soffer D, Keshet E (1992). Vascular endothelial growth factor induced by hypoxia may mediate hypoxia‐initiated angiogenesis. Nature 359: 843–845.
34. Siddiq A, Aminova LR, Ratan RR (2007). Hypoxia inducible factor prolyl 4‐hydroxylase enzymes: center stage in the battle against hypoxia, metabolic compromise and oxidative stress. Neurochem Res 32: 931–946.
35. Smallbone K, Gatenby RA, Gillies RJ, Maini PK, Gavaghan DJ (2007). Metabolic changes during carcinogenesis: potential impact on invasiveness. J Theor Biol 244: 703–713.
36. Soh Y, Jeong KS, Lee IJ, Bae MA, Kim YC, Song BJ (2000). Selective activation of the c‐Jun N‐terminal protein kinase pathway during 4‐hydroxynonenal‐induced apoptosis of PC12 cells. Mol Pharmacol 58: 535–541.
37. Soh Y, Shin MH, Lee JS, Jang JH, Kim OH, Kang H et al. (2003). Oxidative DNA damage and glioma cell death induced by tetrahydropapaveroline. Mutat Res 544: 129–142.
38. Soh Y, Song BJ, Jeng J, Kallarakal AT (1998). Critical role of arg433 in rat transketolase activity as probed by site‐directed mutagenesis. Biochem J 333: 367–372.
39. Takeda K, Cowan A, Fong GH (2007). Essential role for prolyl hydroxylase domain protein 2 in oxygen homeostasis of the adult vascular system. Circulation 116: 774–781.
40. Temes E, Martin‐Puig S, Acosta‐Iborra B, Castellanos MC, Feijoo‐Cuaresma M, Olmos G et al. (2005). Activation of HIF‐prolyl hydroxylases by R59949, an inhibitor of the diacylglycerol kinase. J Biol Chem 280: 24238–24244.
41. Tuckerman JR, Zhao Y, Hewitson KS, Tian YM, Pugh CW, Ratcliffe PJ et al. (2004). Determination and comparison of specific activity of the HIF‐prolyl hydroxylases. FEBS Lett 576: 145–150.
42. Wang J, Pantopoulos K (2005). The pathway for IRP2 degradation involving 2‐oxoglutarate‐dependent oxygenase(s) does not require the E3 ubiquitin ligase activity of pVHL. Biochim Biophys Acta 1743: 79–85.
43. Zagorska A, Dulak J (2004). HIF‐1: the knowns and unknowns of hypoxia sensing. Acta Biochim Pol 51: 563–585.